medigraphic.com
ISSN 1561-3038 (Print)

2021, Number 4

<< Back Next >>

Rev Cubana Med Gen Integr 2021; 37 (4)

Clinical-biochemical and fibroelastometric results of the mare's milk application in non-alcoholic steathepatitis

Bimbetov B, Shanazarov N, Aitbaeva S, Bakytzhanuly A, Utepbergenova G

Language: English
References: 30
Page:
PDF size: 333.29 Kb.


ABSTRACT

Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world, representing the hepatic component of metabolic syndrome, and currently affects an average of 20-33% of the adult population. Non-alcoholic steatohepatitis (NASH) is a severe form of NAFLD and is a consequence of overweight, obesity, and metabolic syndrome.
Objective: The study aimed to evaluate the effectiveness of the use of freeze-dried mare's milk in NASH.
Methods: Clinical-biochemical, ultrasound, and fibroelastometric research methods were used in NASH patients receiving mare's milk in comparison with the control groups.
Results: The result of the study demonstrates noticeable gain not only in the clinical symptoms of the disease but also in the laboratory and instrumental indicators, as well as health improvement and a decrease in symptoms of concomitant pathology.
Taking mare's milk not only normalized liver biochemical parameters but also decreased cholesterol metabolism (total cholesterol, LDL, TG), the degree of liver steatosis, and existing hepatomegaly declined too. This pleiotropic effect of mare's milk points to the pathogenetic feasibility for the use of Saumal in NAFLD, including NASH.
Conclusions: Addressing the problems of healthy nutrition in NASH, mare's milk can be considered as a pathogenetically justified, highly effective, and affordable natural therapeutic and prophylactic agent. The value of the product is determined by its multicomponent balanced qualitative composition. Hepatoprotective, hypocholesterolemic, and lipotropic properties of mare's milk in this pathology are marked.


REFERENCES

  1. Rinella ME, Sanyal AJ. Management of NAFLD: a stagebased approach. Nat Rev Gastroenterol Hepatol. 2016 [acceso: 24/02/2016];13:196-205. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/26907882/

  2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 [acceso: 22/02/2016];64:73-84. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/26707365/

  3. Diehl AM, Day C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. New England Journal of Medicine. 2017 [acceso: 23/11/2017];377(21):2063-72. Disponible en: Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMra1503519

  4. Ivashkin VT, Mayevskaya Marina V, Pavlov ChS, Tikhonov IN, Shirokova YeN, Buyeverov AO, et al. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. // Russian Journal of Gastroenterology, Hepatology and Coloproctology. 2016 [acceso: 27/06/2017];2:24-42. Disponible en: Disponible en: https://www.gastro-j.ru/jour/article/view/31?locale=en_US

  5. Maevskaya EA, Kucheryavyy YA, Maev IV. Intestinal microflora and non-alcoholic steatohepatitis: from mechanisms of pathogenesis to pathogenetic therapy. Attending Physician. 2014 [acceso: 27/06/2017]. Disponible en: Disponible en: https://www.lvrach.ru/2014/08/15436028

  6. Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. Journal of Pediatric Gastroenterology and Nutrition. 2013 [acceso: 05/05/2013];56(5):461-8. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/23287807/

  7. Machado MV, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Annals of Hepatology. 2012 [acceso: 22/07/2012];11(4):440-9. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/22700625/

  8. Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;13;7:11. DOI: https://doi.org/10.20517/2394-5079.2020.134

  9. Komshilova KA, Troshina EA, Butrova SA. Non-alcoholic fatty liver disease in obesity. Obesity and Metabolism. 2011 [acceso: 11/07/2011];3:3-11. https://cyberleninka.ru/article/n/nealkogolnaya-zhirovaya-bolezn-pecheni-pri-ozhirenii/viewer

  10. Parnell JA, Raman M, Rioux KP, Reimer RA. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int. 2012;32(5):701-11. DOI: https://doi.org/10.1111/j.1478-3231.2011.02730.x

  11. Zhangabylov AK. Saumal, koumiss-medicinal properties. Riga: Lamber Academia Publishing House; 2018 [access: 27/08/2018]. Disponible en: Disponible en: https://www.morebooks.de/store/gb/book/isbn/978-3-659-51935-2

  12. Bimbetov B, Zhangobylov A, Aitbaeva S, Benberin V, Zollmann H, Musaev A, et al. Mare's milk: therapeutic and dietary properties. Bulletin of the National Academy of Sciences of the Republic of Kazakhstan. 2019 [acceso: 10/06/2019];3(379):52-58. Disponible en: Disponible en: https://journals.nauka-nanrk.kz/bulletin-science/article/view/1460

  13. Bimbetov B, Zhangobylov A, Aitbaeva S, Bakytzhanuly A. The mare’s milk application in non-alcoholic ratty liver diseases. Medicine (Almaty). 2019 [acceso: 14/11/2019];9(207):66-72. Disponible en: Disponible en: https://www.medzdrav.kz/images/magazine/medecine/2019/2019-9/66-72.pdf

  14. Kushugulova A, Kozhakhmetov S, Sattybayeva R, Nurgozhina А, Ziyat А, Yadav Н, et al. The mare’s milk as a prospective functional product. Functional foods in Health and desease. 2018 [acceso: 08/11/2018];8(11):537-43. Disponible en: Disponible en: https://www.researchgate.net/publication/332232748_Mare's_milk_as_a_prospective_functional_product

  15. Kanareikina SG, Davydova AA, Kanareikin VI. Therapeutic and prophylactic properties of mare's milk S.G. Bulletin of beef cattle breeding. 2016 [acceso: 24/06/2016];3(95):99-103. Disponible en: Disponible en: https://cyberleninka.ru/article/n/lechebno-profilakticheskie-svoystva-kobyliego-moloka/viewer

  16. Mazhitova A, Kulmurzaev A. Physiologically functional components of mare's milk. Journal of Engineering Manas. 2015 [acceso: 01/10/2015];3(2):1-8. Disponible en: Disponible en: https://dergipark.org.tr/en/pub/mjen/issue/40443/484321

  17. Brezovečki A, Čagalj M, Antunac N, Mikulec N, Bendelja DL. Production, composition and properties of mare's milk. Dairy products. 2014 [acceso: 01/04/2014];64(4):217-22. Disponible en: Disponible en: https://hrcak.srce.hr/index.php?show=clanak&id_clanak_jezik=191960

  18. Markiewicz-Keszycka M, Wójtowski J, Czyzak-Runowska G, Kuczyńska В, Puppel К, Krzyżewski J, et al. Concentration of selected fatty acids, fat-soluble vitamins and b-carotene in late lactation mares’ milk. International Dairy Journal. 2014 [acceso: 29/09/2014];38(1):31-6. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S095869461400079X?via%3Dihub

  19. Kudayarova RR, Gilmutdinova LT, Yamaletdinov KS, Gilmutdinov AR, Gabdelhakova LT, Zinnatullin RKh. Historical aspects of the use in medicine kumis. Bulletin of Siberian Medicine. 2010. [acceso: 05/09/2010];5:186-190. Disponible en: Disponible en: https://bulletin.tomsk.ru/jour/article/view/1685

  20. Zollmann H. Production of bio-mare's milk, koumiss and their use in Europe. Materials of the international congress “Gastroenterology-2015ˮ Modern problems of pediatric and adult gastroenterology. From scientific achievements to clinical practice. Almaty; 2015.

  21. Directory of diseases Med Element. Fatty degeneration of the liver. 2015 [acceso: 28/09/2020]. Disponible en: Disponible en: https://diseases.medelement.com/disease/жировая-дегенерация-печени-k76-0/4827

  22. Republican Center for Healthcare Development of the Ministry of Healthcare of the RK. Non-alcoholic fatty liver disease in adults. Clinical protocol for diagnosis and treatment. 2015 [acceso: 28/09/2020]. Disponible en: Disponible en: https://diseases.medelement.com/disease/неалкогольная-жировая-болезнь-печени-у-взрослых/14501

  23. Polosukhina A, Vinnitskaya EV, Khaimenova TY, Sandler YG. Non-alcoholic steatohepatitis: the problem of modern diagnostics. Consilium Medicum. Gastroenterology (Annex.). 2018 [acceso: 24/01/2018];1:23-9. Disponible en: Disponible en: https://www.elibrary.ru/item.asp?id=35076970

  24. Nikonov EL, Aksenov VA. Modern approaches to the diagnosis and treatment of non-alcoholic fatty liver disease. Preventive Medicine. 2018 [acceso: 21/03/2018];3:62-9. Disponible en: Disponible en: https://www.mediasphera.ru/issues/profilakticheskaya-meditsina/2018/3/1230549482018031062

  25. Tsukanov VV, Vasyutin AV, Tonkikh YL. Modern principles of management of patients with non-alcoholic fatty liver disease. Doctor Ru. 2019 [acceso: 12/04/2019];3(158):11-4. Disponible en: Disponible en: https://journaldoctor.ru/catalog/gastroenterologiya/sovremennye-printsipy/

  26. Naydanova EG, Kozlova NM. The main directions in the treatment of non-alcoholic fatty liver disease. Bulletin of the Buryat State University. 2015 [acceso: 24/12/2015];12:123-9. https://cyberleninka.ru/article/n/osnovnye-napravleniya-v-lechenii-nealkogolnoy-zhirovoy-bolezni-pecheni

  27. Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rossle M, Cordes HJ, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebocontrolled trial. Hepatology. 2010 [accesso: 23/07/2010];52:472-9. Disponible en: Disponible en: https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.23727

  28. Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clinical Gastroenterology, Hepatology. 2006;4:1537-43. [access: 04/12/2006]. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/17162245/

  29. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). Clinical practice guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease. Journal of Hepatology. 2016 [access: 06/04/2016];64:1388-1402. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/27062661/

  30. Chalasani N, Younossi Z, Lavine JE, Mae Deiehl A, Brunt EM, Cusi K, et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012 [access: 06/04/2012];142:1592-1609. Disponible en: Disponible en: https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.25762




2020     |     www.medigraphic.com